NKTR-214

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

18 competitors in Sarcoma

#DrugCompanyPhaseTrials

1

Opdivo

Bristol-Myers Squibb

Phase 2

22

Keytruda

Merck & Co.

Phase 2

23

Tecentriq

Roche

Phase 2

14

IC-Green

PProvepharm SAS

Phase 2

15

Amtagvi

IIovance Biotherapeutics, Inc.

Phase 2

16

Talimogene Laherparepvec

Amgen

Phase 2

37

Biological

NNational Environment Agency, Singapore

Phase 1

18

Rapamune

PPrism Pharmaceuticals

Preclinical

19

NEULASTA

Amgen

Preclinical

110

NKTR-214

Bristol-Myers Squibb

Phase 2

1Show 6 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors2 trials

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Completed·NNektar Therapeutics·Phase 1/2·NCT02869295·28 enrolled

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Terminated·NNektar Therapeutics·Phase 1/2·NCT03138889·162 enrolled

Prostate1 trial

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Completed·PParker Institute for Cancer Immunotherapy·Phase 1·NCT03835533·43 enrolled

Advanced Solid Tumors1 trial

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Completed·Bristol-Myers Squibb·Phase 1·NCT03745807·3 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT04936841·5 enrolled

Metastatic Melanoma1 trial

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Completed·Bristol-Myers Squibb·Phase 3·NCT03635983·783 enrolled

3 more indications

Lymphoma1 trial

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Withdrawn·CCalithera Biosciences, Inc·Phase 1·NCT03772288

Resistant Cancer1 trial

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Terminated·Bristol-Myers Squibb·Phase 1/2·NCT04730349·15 enrolled

Sarcoma1 trial

A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma (CA209-9EM)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03282344·88 enrolled

Details

Drug Info

Related News